Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial.

@article{Oosten1997TreatmentOM,
  title={Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial.},
  author={Bob W. van Oosten and Marina Lai and Suzanne Hodgkinson and Frederik Barkhof and David H. Miller and Ivan F. Moseley and Alan J. Thompson and Peter Rudge and Allan McDougall and James G. Mcleod and Herman J. Ad{\`e}r and Chris H. Polman},
  journal={Neurology},
  year={1997},
  volume={49 2},
  pages={351-7}
}
We report the results of a randomized, double-blind, placebo-controlled exploratory trial of the chimeric monoclonal anti-CD4 antibody cM-T412 in 71 patients suffering from active relapsing-remitting and secondary progressive multiple sclerosis. Infusion of the antibody produced frequent but usually minor side effects and resulted in a long-lasting reduction of circulating CD4-positive T cells. There was no significant effect on the primary measure of efficacy, the number of active lesions on… CONTINUE READING
68 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 68 extracted citations

Similar Papers

Loading similar papers…